Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sun Primes Late-Stage Psoriasis Asset With Samsung Manufacturing Deal

Executive Summary

Sun Pharma has firmed up a manufacturing pact for tildrakizumab with Samsung BioLogics, securing supplies of its late-stage psoriasis asset in an increasingly competitive segment. The deal also underscores Samsung’s expanding stature as a frontline CMO in the biologics space.


Related Content

Indo-Korean Pharma Linkages: A New Emerging Asian Front?
Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended
Sun Q3 Profits Dive, Halol Resolution Stays Pivotal To Trigger Reset
Deal Watch: Entasis, GARDP Partner On Novel Antibiotic For Drug-Resistant Gonorrhea
Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts